Newsweek: The Case for Ibogaine: Kentucky's Opportunity to Lead in the Fight Against Opioid Addiction | Opinion
As the opioid epidemic continues to grip our nation, claiming lives, destroying families, and burdening communities, it is imperative that we explore every viable solution. Among these potential solutions is a powerful, natural, non-addictive substance known as ibogaine. As voices that have served in political and military capacities, we unite in our appeal to the Kentucky Opioid Abatement Advisory Commission (KYOAAC): Allocate $42 million for ibogaine research. Kentucky has a unique chance to pioneer a revolutionary approach to combat opioid addiction and pave the way for the entire country.
When Bryan Hubbard was appointed Executive Director of the newly formed Kentucky Opioid Abatement Advisory Commission in 2021, he had already been tracking psychedelic-assisted therapies in the media for three years.
Marijuana Moment: Veteran Access To Psychedelics Requires Balance Of Speed And Caution, Says Panel With VA And Former CDC Officials
Experts and advocates—including a Department of Veterans Affairs (VA) official and a former director of the Centers for Disease Control and Prevention (CDC)—recently convened for a Harvard University panel to discuss efforts to expand veteran access to psychedelic-assisted therapy.
Pharmacy Times: Psychedelic-Assisted Therapy Is Life-Changing for Veterans With PTSD, Yet Access to These Therapies Remain Outside the United States
Pharmacy Times interviewed Marcus Capone and Amber Capone, the co-founders of Veterans Exploring Treatment Solutions (VETS), on the current opportunities available for US veterans to seek psychedelic-assisted therapies for post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBIs).